Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20
BW Businessworld

'We Will Have $100 Mn Valuation Very Soon'

Photo Credit :

The second edition of BW Healthcare Summit held in New Delhi on June 5 attracted major healthcare industry players. Ruchi Dass, founder and CEO of the global strategy consulting firm HealthCursor, spoke to BW|Businessworld's Arshad Khan about services which differentiate her firms with others, informatics in healthcare, expansion in the US market and more. Excerpts:
 
Your firm HealthCursor has grown rapidly in a very short span of time. What is the reason behind the success and what differentiates HealthCursor from other consultant firms?
The biggest difference is that we work with start-ups belonging to large organisations and those less than $50 million in valuation. The area where we are uniquely placed is that we help start-ups find new markets. Beside providing strategic inputs like other consulting companies, we also help in identifying the right partners, business leads, provide first deal for start-ups and are also involved in operational capacity.  
 
 
What are HealthCursor’s future expansion plans?
At present, I am working on the expansion of a new company called Enlightiks in which I am a CMO. It is big data analytic company. We are present in India and has tie up with 1,600 hospitals. We are rapidly progressing into the US and Asian market. The idea is to expand ourselves so that we become the biggest data repository to healthcare in the world.
 
One of your services is called Big Data. How much work has been done to involve Big Data in healthcare?
In India, predictive analysis is still in a nascent stage. It is a concept which is very popular on US because of meaningful use and rapid digitisation of data.  It will help in facilitating healthcare. It will help in studying patients whose data is already in the repository. The service will definitely lead to growth in operational revenue and clinical performance.
 
What is the turnover of your company? Do you have any plan to go public?
The company is still pretty small. We are expanding very fast, especially in the US market. IPO is very probably 3 to 4 years down the lane. We will have 100 million worth of valuation very soon.  
 
You have been also working with WHO to achieve MDG. WHat is your role and how far has the work been done?
WHO has associated our company HealthCursor. We are working mainly in two areas. One is the care for women and children on the other hand we are also working on the ICT advisory group for mhealth deployment in remote areas.